Simon Says: EEG Meets Cloud Computing
In June at the DIA conference, Lifelines’ CEO, Simon Griffin, was interviewed by PharmaVOICE Editor Taren Grom. Introduced as a thought leader in neurodiagnostics, and rightfully so, Simon was asked to discuss our industry-leading Cloud-based solutions.
EEG Meets Cloud Computing
Simon Griffin, CEO
Lifelines Neurodiagnostic Systems, Inc.
A 2011 report from the Tufts Center for the Study of Drug Development suggests that CNS trials are far more complex and costly for pharmaceutical companies to develop than other medicines. Compounds for CNS drugs spend about 8.1 years in clinical testing and 1.9 years in the regulatory process. It can take up to 18 years to develop a drug from testing in the lab to approval for patient use.
Only 8.2% of new CNS agents that begin testing on humans will actually reach the marketplace; this is compared with 15% for all other drugs overall. With an estimate of only 46% success rate in Phase III trials for CNS drugs, compared with an average of 66% for all other drugs, the cost of CNS drug development is among the highest in any therapeutic area.
Failed studies tend to occur late in the clinical development stages when costs are at their highest. Spending millions of dollars on new CNS meds, only to have them fail in the clinical trial process, is a huge risk to pharmaceutical companies. When a new drug finally reaches the point of human testing, each individually enrolled subject represents an enormous investment in time and money. And for compound efficacy that is being measured with EEG, technical and recording difficulties simply cannot be the cause for these new meds to fail.
Read the rest of the article here.